Published on Novartis Belgie (https://prod.my.novartis.be)

Home > Printer-friendly > Kesimpta patient cases

Kesimpta patient cases [1]

Novartis Neuroscience Academy

 

Summary

  1. Treatment switch from Gilenya® to Kesimpta®
  2. Early switch from teriflunomide to Kesimpta®
  3. Treatment switch from Gilenya® to Kesimpta®
  4. First line switch from dimethyl fumarate to Kesimpta®
  5. Increased tolerability: ocrelizumab to Kesimpta®
  6. Treatment switch from cladribine, to Kesimpta®

 

Source URL:https://prod.my.novartis.be/nl/kesimpta-patient-cases?hash=84dc0910ae085b0ed411edc36ad0e91de22c8590226a5672193d1502ea1bb37c

Links
[1] https://prod.my.novartis.be/nl/kesimpta-patient-cases